Trial Profile
A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Antithymocyte globulin; Ciclosporin
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Acronyms RACE
- 06 Jan 2022 Primary endpoint (CR rate) has been met, according to results published in the New England Journal of Medicine.
- 06 Jan 2022 Results published in the New England Journal of Medicine
- 21 Dec 2020 Status changed from active, no longer recruiting to completed.